Belite Bio, Inc (BLTE): Price and Financial Metrics
BLTE Price/Volume Stats
Current price | $69.90 | 52-week high | $70.36 |
Prev. close | $66.61 | 52-week low | $31.00 |
Day low | $65.75 | Volume | 134,100 |
Day high | $70.00 | Avg. volume | 51,637 |
50-day MA | $53.10 | Dividend yield | N/A |
200-day MA | $47.14 | Market Cap | 2.14B |
BLTE Stock Price Chart Interactive Chart >
Belite Bio, Inc (BLTE) Company Bio
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
BLTE Price Returns
1-mo | N/A |
3-mo | N/A |
6-mo | N/A |
1-year | N/A |
3-year | N/A |
5-year | N/A |
YTD | N/A |
2023 | N/A |
2022 | N/A |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...